Commentary

Portfolio allocations remained largely unchanged, and new contributions continued to favor target date and equity funds.

More patients are buying important medications outside plan boundaries.

Biologics perform miracles for patients but wreck health plan budgets. Competitors help.

Patients deserve an individualized coverage determination based on the facts of their case — not assumptions.

Employers will need to take stock of any changed reporting obligations and assess whether they are going to continue collecting employee demographic information in light of the changes.

Menopause isn't going away, and neither are the women who are tired of being overlooked.